Oberye, J.J., Mannaerts, B.M., Huisman, J.A. and Timmer, C.J. (1999) Pharmacokinetic and Pharmacodynamic Characteristics of Ganirelix (Antagon/Orgalutran). Part II. Dose-Proportionality and Gonadotropin Suppression after Multiple Doses of Ganirelix in Healthy Female Volunteers. Fertility and Sterility, 72, 1006-1012.

has been cited by the following article:

• TITLE: GnRH Antagonist Protocol: Is It Optimal for All Patients of Different Ages Undergoing In Vitro Fertilization and Embryo Transfer?

  AUTHORS: Weijie Xing, Haiyan Lin, Qingxue Zhang

  KEYWORDS: GnRH Agonist, GnRH Antagonist, IVF-ET

  JOURNAL NAME: Advances in Sexual Medicine, Vol.7 No.4, September 22, 2017

  ABSTRACT: Background: To assess the effect of these two protocols in patients of different ages. Methods: 1923 in vitro fertilization and embryo transfer (IVF-ET) cycles were divided into two groups: a GnRH-ant protocol group and GnRH-a long protocol group, and then every group were subdivided into four age ranges. The general materials and IVF outcomes were compared. Results: The incidence of OHSS fluctuated from 0% to 2.37% with GnRH-ant protocol, which was significantly lower than another (P P Conclusion: The antagonist protocol should be considered in patients with a high ovarian response (e.g., PCOS patients) to avoid OHSS. Older patients (>35 years) could be treated with the antagonist protocol.